Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD0.2 Million in Private Placement of Shares 12
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 13
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 15
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 17
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 18
Innate Immunotherapeutics Completes IPO For US$9 Million 19
Acquisition 21
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 21
Amplia Therapeutics Ltd – Key Competitors 22
Amplia Therapeutics Ltd – Key Employees 23
Amplia Therapeutics Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Jul 30, 2018: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report of the year 2018 25
Corporate Communications 26
May 28, 2018: Innate Immunotherapeutics Names Dr. Warwick Tong As Chairman 26
Legal and Regulatory 27
Aug 08, 2018: Congressman Christopher Collins And Others Charged In Manhattan Federal Court With Insider Trading And Lying To Federal Law Enforcement Agents 27
Product News 30
06/21/2017: Innate Immunotherapeutics receives FDA clearance for MIS416 Investigational New Drug application 30
03/07/2017: Multiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists Meeting 31
Clinical Trials 32
Oct 20, 2017: Innate Immunotherapeutics Provides Corporate Update 32
Jul 21, 2017: No change to outcome of MIS416 trial in patients with SPMS following additional data analysis 33
Jun 27, 2017: Innate Immunotherapeutics announces top-line results for trial of MIS416 in patients with secondary progressive multiple sclerosis 34
Apr 20, 2017: Completion of Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis 36
Feb 28, 2017: Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis on schedule to complete by end of April 2017 37
Other Significant Developments 38
Sep 05, 2018: Innate Immunotherapeutics changes name to Amplia Therapeutics and ASX stock code to ATX 38
Oct 30, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 39
Jul 28, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD0.2 Million in Private Placement of Shares 12
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 13
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 15
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 17
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 18
Innate Immunotherapeutics Completes IPO For US$9 Million 19
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 21
Amplia Therapeutics Ltd, Key Competitors 22
Amplia Therapeutics Ltd, Key Employees 23
Amplia Therapeutics Ltd, Subsidiaries 24
List of Figures
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9